Gsa Capital Partners LLP Rocket Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$12.37 - $18.41 $411,834 - $612,924	33,293 Added 156.39%	54,582 $871,000
Q2 2022 Aug 09, 2022	BUY	$7.96 - $16.64 $169,460 - $354,248	21,289 New	21,289 $293,000
Q1 2022 May 11, 2022	SELL	$13.16 - $23.68 $469,864 - $845,470	-35,704 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$21.52 - $36.02 $768,350 - $1.29 Million	35,704 New	35,704 $779,000
Q1 2021 May 10, 2021	SELL	$43.34 - $65.91 $290,334 - $441,531	-6,699 Closed	0 $0
Q4 2020 Feb 03, 2021	SELL	$23.3 - $59.57 $320,771 - $820,100	-13,767 Reduced 67.27%	6,699 $367,000
Q3 2020 Nov 06, 2020	BUY	$20.5 - $28.59 $419,553 - $585,122	20,466 New	20,466 $468,000

209

93.1M

319K

70.3K

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $809M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.